fda glp-1 warning letters october 2025 news issued 30 to telehealth companies for false and misleading claims about compounded products. This marks the second round of enforcement action since the agency's September crackdown on misleading FDA issued 25 warning letters
Description
There is no dose equivalency between formats
Both animal and human studies published in English were included
The research here is at the ingredient level, not finished-product clinical trial data
Basic characteristics A pooled population of 840 patients was included, with 469 individuals in GLP1RAs arm and 371 individuals in control arm
doi: 10.1080/10408398.2016.1252712 [DOI] [PubMed] [Google Scholar] 29
